Precision Medicine in Oncology® | Specialty

New Research Results Spotlight Rare Molecular Subtypes in NSCLC

May 10th 2023

Although molecularly targeted therapies have transformed the treatment paradigm for NSCLC, the kaleidoscope of genomic alterations that affects subsets of patients is straining the limits of current diagnostic and clinical discovery approaches.

FDA Grants 501K Clearance to Bladder EpiCheck for Surveillance in NMIBC

May 5th 2023

The FDA has granted 510K clearance to Bladder EpiCheck for use as a noninvasive method for surveillance of tumor recurrence in previously diagnosed patients with non–muscle invasive bladder cancer, in conjunction with cystoscopy.

FDA Approves Companion Diagnostic for Mobocertinib in Advanced NSCLC With EGFR Exon 20 Insertion Mutations

May 4th 2023

The FDA has approved FoundationOne® Liquid CDx as a companion diagnostic for mobocertinib in patients with locally advanced or metastatic non–small cell lung cancer harboring EGFR exon 20 insertion mutations.

Adagrasib Demonstrates Promising Activity in KRAS G12C–Mutated Solid Tumors

May 3rd 2023

Treatment with adagrasib monotherapy led to clinically meaningful activity and a manageable safety profile in patients with KRAS G12C–mutated solid tumors.

Dr Sahin on the Investigation of Milademetan and ONC201 in Solid Tumors

May 3rd 2023

Ilyas Sahin, MD, discusses the investigation of milademetan in combination with imipridone ONC201 as a synergistic combination in solid tumors.

VT3989 Shows Activity, Tolerability in Mesothelioma and Other NF2-Mutated Solid Tumors

April 26th 2023

VT3989, a first-in-class YAP/TEAD inhibitor, showcased durable antitumor activity and tolerability in patients with malignant mesothelioma and other solid tumors harboring NF2 mutations, according to data from a phase 1 trial presented at the 2023 AACR Annual Meeting.

FDA Places Partial Clinical Hold on Trial of FHD-609 in Synovial Sarcoma and SMARCB1-Deleted Tumors

April 24th 2023

The FDA has placed a partial clinical hold on the phase 1 trial evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and early clinical activity of FHD-609 in patients with advanced synovial sarcoma and SMARCB1-deleted tumors.

LY3537982 Demonstrates Tolerability and Preliminary Efficacy in KRAS G12C–mutated Advanced Solid Tumors

April 23rd 2023

Joshua K. Sabari, MD, shares how the unique pharmacokinetics and mechanism of action for LY3537982 supported its investigation in the LOXO-RAS- 20001 study, findings presented at AACR, and how this research could address unmet needs in patients with KRAS G12C–mutant solid tumors.

Novel Methylation-Based Platform Shows Promise for Multicancer Early Detection

April 21st 2023

A genome-wide methylome enrichment platform demonstrated efficacy in detecting early-stage, low-shedding cancers with limited circulating tumor DNA.

Expanded Genomic and Early-Detection Testing Define Next Level of Precision Oncology Screening and Management

April 20th 2023

Early Success With Olaparib Plus Selumetinib Leads to Further Exploration in RAS-mutated Gynecologic Cancers

April 14th 2023

Shannon N. Westin, MD, MPH, FACOG, shares preclinical data that provided the impetus for the SOLAR trial of olaparib and selumetinib in patients with RAS-mutated gynecologic cancers, key findings from the dose-escalation and -expansion portions of the research, and next steps with the combination.

Cytokines Play Integral Role in Cancer Immune Cycle

April 3rd 2023

In the setting of cancer, cytokines contribute to cells’ antitumor response, cell damage, inflammation, angiogenesis, metastasis, and other cellular processes that enable tumor survival

Applied Molecular Medicine Signals the Future of Personalized, Preventive Cancer Care

April 3rd 2023

Andre Goy, MD, discusses advances in the field of oncology that prompted the development of the Hennessy Institute, how early cancer detection can improve patient outcomes, and the importance of employing accessible cancer prevention strategies.

Precision Medicine Takes On an Increasingly Relevant but Misunderstood Role in Oncology

March 28th 2023

The evaluation of diagnostic quality in precision medicine should almost certainly be assessed by standards different from those used in drug development.

Erdafitinib Elicits Responses in High- and Intermediate-Risk NMIBC Harboring FGFR3/2 Alterations

March 22nd 2023

Siamak Daneshmand, MD, shed light on the phase 2 THOR-2 study evaluating different cohorts of patients with recurrent NMIBC, key findings from cohorts 2 and 3, and how ongoing research seeks to move the needle forward with novel drug delivery methods.

Dr. Henick on Further Exploring the Immune Microenvironment in Lung Cancer

March 20th 2023

Brian Henick, MD, discusses the importance of further exploring biomarkers in the immune microenvironment for immunotherapy in patients with lung cancer.

FDA Approves Dabrafenib Plus Trametinib for Pediatric Patients With BRAF V600E–Mutated Low-Grade Glioma

March 16th 2023

The FDA has approved dabrafenib with trametinib for the treatment of pediatric patients 1 year of age and older with low-grade glioma with a BRAF V600E mutation who require systemic therapy.

Traveling Through the Lung Cancer Treatment Paradigm: Taking TKI-Related AEs Into Consideration for NSCLC

March 15th 2023

In this sixth episode of OncChats: Traveling Through the Lung Cancer Treatment Paradigm, Aaron Franke, MD, discusses the consideration of adverse effects related to treatment with TKIs patients in non–small cell lung cancer.

Vorasidenib Meets PFS End Point in IDH1/2-Mutant Low-Grade Glioma

March 14th 2023

Vorasidenib monotherapy elicited a statistically significant and clinically meaningful improvement in progression-free survival compared with placebo in patients with residual or recurrent IDH1/2-mutant low-grade glioma.

Adjuvant Targeted Therapies Could Continue to Shift the Treatment Paradigm in NSCLC

March 14th 2023

Adjuvant osimertinib and other targeted therapies, such as KRAS G12C inhibitors, could continue to change the perioperative treatment landscape in non–small cell lung cancer.